menu

Best Practices in the Use of Long-Acting Injectables in Bipolar Disorder – Part 1

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Best Practices in the Use of Long-Acting Injectables in Bipolar Disorder – Part 1

0.50 credits
30 minutes
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    This Expert Exchange webcast is designed to help clinicians determine the appropriate time to initiate LAI therapy in patients with bipolar disorder, and how to discuss that treatment decision with patients.

  • Target Audience

    This activity has been designed to meet the educational needs of psychiatrists, primary care physicians and other mental healthcare professionals.

  • Educational Objectives

    Upon completion of this activity, participants will be better able to do the following:

    • Evaluate evidence for disease progression in bipolar disorder and the impact of early intervention.
    • Identify patients at risk for treatment non-adherence who may benefit from earlier use of long-acting injectable antipsychotics.
    • Discuss place in therapy and best practices in prescribing of long-acting injectable antipsychotics in bipolar disorder.
    • Examine collaborative care models between psychiatrists and primary care clinicians that may improve quality of care for patients with bipolar disorder.
  • Financial Support

    This activity is supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.

  • Provider(s)/Educational Partner(s)

    Jointly provided by Medical Education Resources and Novus Medical Education.

  • Accreditation and Credit Designation Statements

    Joint Accreditation Statement
    In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Novus Medical Education. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Credit Designation for Physicians
    MER designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclosure of Conflicts of Interest

    MER requires faculty, instructors, authors, planners, directors, managers, reviewers and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is t producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified andmitigated prior to initiation of the planning phase for an activity

    MER has mitigated and disclosed to learners all relevant conflicts of interestdisclosed by staff, planners, faculty/authors, peer reviewers or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity. The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:

    Dr. McIntyre discloses the following relationships:
    Advisor/Consultant and Speakers Bureau: Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, AbbVie

    Dr. Sajatovic discloses the following relationships:
    Advisor/Consultant: Alkermes, Janssen, Myriad, Otsuka.
    Research Support: Alkermes, Nuromate, Otsuka.

    The directors, planners, managers and reviewers of this activity reported no relevant financial relationships with an ineligible company during the past 24 months

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Method of Participation

    There are no fees for participating and receiving CME credit for this activity. To claim credit, participants must complete the following:

    1. Read the educational objectives, accreditation information and faculty disclosures at the beginning of this activity.
    2. Complete the pre-test.
    3. View the webcast.
    4. Complete the post-test and evaluation.
    5. Physicians who receive a grade of 75% or better on the post-test and complete the evaluation will receive a CME certificate.
    6. All other participants who receive a grade of 80% or better on the post-test and complete the evaluation will receive a Certificate of Participation.
  • CME Provider

    For information about the certification of this activity, please contact MER at info@cmepartner.org or 800.421.3756.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    This Expert Exchange webcast is designed to help clinicians determine the appropriate time to initiate LAI therapy in patients with bipolar disorder, and how to discuss that treatment decision with patients.

  • Target Audience

    This activity has been designed to meet the educational needs of psychiatrists, primary care physicians and other mental healthcare professionals.

  • Educational Objectives

    Upon completion of this activity, participants will be better able to do the following:

    • Evaluate evidence for disease progression in bipolar disorder and the impact of early intervention.
    • Identify patients at risk for treatment non-adherence who may benefit from earlier use of long-acting injectable antipsychotics.
    • Discuss place in therapy and best practices in prescribing of long-acting injectable antipsychotics in bipolar disorder.
    • Examine collaborative care models between psychiatrists and primary care clinicians that may improve quality of care for patients with bipolar disorder.
  • Financial Support

    This activity is supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.

  • Provider(s)/Educational Partner(s)

    Jointly provided by Medical Education Resources and Novus Medical Education.

  • Accreditation and Credit Designation Statements

    Joint Accreditation Statement
    In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Novus Medical Education. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Credit Designation for Physicians
    MER designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclosure of Conflicts of Interest

    MER requires faculty, instructors, authors, planners, directors, managers, reviewers and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is t producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified andmitigated prior to initiation of the planning phase for an activity

    MER has mitigated and disclosed to learners all relevant conflicts of interestdisclosed by staff, planners, faculty/authors, peer reviewers or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity. The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:

    Dr. McIntyre discloses the following relationships:
    Advisor/Consultant and Speakers Bureau: Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, AbbVie

    Dr. Sajatovic discloses the following relationships:
    Advisor/Consultant: Alkermes, Janssen, Myriad, Otsuka.
    Research Support: Alkermes, Nuromate, Otsuka.

    The directors, planners, managers and reviewers of this activity reported no relevant financial relationships with an ineligible company during the past 24 months

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Method of Participation

    There are no fees for participating and receiving CME credit for this activity. To claim credit, participants must complete the following:

    1. Read the educational objectives, accreditation information and faculty disclosures at the beginning of this activity.
    2. Complete the pre-test.
    3. View the webcast.
    4. Complete the post-test and evaluation.
    5. Physicians who receive a grade of 75% or better on the post-test and complete the evaluation will receive a CME certificate.
    6. All other participants who receive a grade of 80% or better on the post-test and complete the evaluation will receive a Certificate of Participation.
  • CME Provider

    For information about the certification of this activity, please contact MER at info@cmepartner.org or 800.421.3756.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule27 Nov 2021
Webpack App